{ "checked": "2026-10-26", "page": "https://jabbitapp.com/research/senolytics-fisetin-dasatinib-quercetin-longevity-evidence-teardown.html", "dasatinib_label": { "source": "DailyMed SPRYCEL (dasatinib) tablet, E.R. Squibb & Sons, setid 4764f37b-c9e6-4ede-bcc2-8a03b7c521df, SPL version 49, published 2026-09-21", "url": "https://dailymed.nlm.nih.gov/dailymed/drugInfoBySetId.cfm?setid=4764f37b-c9e6-4ede-bcc2-8a03b7c521df", "quotes": [ "SPRYCEL (dasatinib) is indicated for the treatment of adult patients with", "newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase.", "Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy.", "Severe thrombocytopenia, neutropenia, and anemia may occur.", "Use caution if used concomitantly with medications that inhibit platelet function or anticoagulants.", "Fluid retention, sometimes severe, including pleural effusions.", "SPRYCEL may increase the risk of developing PAH which may be reversible on discontinuation.", "Use SPRYCEL with caution in patients who have or may develop prolongation of the QT interval.", "Individual cases of severe mucocutaneous dermatologic reactions have been reported.", "Can cause fetal harm.", "Assess liver function before initiation of treatment and monthly thereafter or as clinically indicated.", "Avoid the use of concomitant strong CYP3A4 inhibitors and grapefruit juice.", "SPRYCEL is a prescription medicine used to treat:" ], "boxed_warning": false }, "fda_dietary_supplements": { "url": "https://www.fda.gov/food/information-consumers-using-dietary-supplements/questions-and-answers-dietary-supplements", "quote": "Under DSHEA, FDA does not have the authority to approve dietary supplements before they are marketed." }, "registry": { "clinicaltrials_gov_intervention_fisetin": 37, "clinicaltrials_gov_intervention_dasatinib_and_quercetin": 22, "unique_records": 55, "lead_sponsor_mayo_clinic": 10, "status_counts": { "ACTIVE_NOT_RECRUITING": 9, "UNKNOWN": 5, "RECRUITING": 12, "TERMINATED": 2, "COMPLETED": 15, "WITHDRAWN": 4, "ENROLLING_BY_INVITATION": 3, "SUSPENDED": 2, "NOT_YET_RECRUITING": 3 }, "records_with_posted_results": [ "NCT02909686", "NCT04063124", "NCT04210986", "NCT04313634", "NCT04537299", "NCT04771611", "NCT05416515", "NCT05422885" ], "selected": { "NCT04313634": [ "COMPLETED", 74, "Sundeep Khosla, M.D.", "2023-06-06", true, "2020-06-09" ], "NCT04210986": [ "COMPLETED", 75, "Steadman Philippon Research Institute", "2023-01-05", true, "2020-01-06" ], "NCT05422885": [ "COMPLETED", 15, "Lewis Lipsitz", "2024-01-24", true, "2022-05-20" ], "NCT03430037": [ "ENROLLING_BY_INVITATION", 40, "Mayo Clinic", "2026-11", false, "2018-02-06" ], "NCT03675724": [ "ENROLLING_BY_INVITATION", 40, "Mayo Clinic", "2026-11", false, "2018-11-15" ], "NCT04685590": [ "ACTIVE_NOT_RECRUITING", 48, "Washington University School of Medicine", "2028-01", false, "2021-12-22" ], "NCT05506488": [ "COMPLETED", 30, "Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)", "2026-02-26", false, "2023-07-05" ], "NCT02874989": [ "COMPLETED", 26, "Wake Forest University Health Sciences", "2019-06-03", false, "2016-12-16" ], "NCT02848131": [ "ENROLLING_BY_INVITATION", 30, "Mayo Clinic", "2027-04", false, "2016-07" ], "NCT04063124": [ "COMPLETED", 5, "The University of Texas Health Science Center at San Antonio", "2021-12-10", true, "2020-02-14" ], "NCT05416515": [ "COMPLETED", 40, "Peter C. Amadio, M.D.", "2024-12-31", true, "2022-10-09" ], "NCT04946383": [ "UNKNOWN", 25, "TruDiagnostic", "2021-12-31", false, "2020-12-16" ], "NCT06018467": [ "COMPLETED", 120, "Odense University Hospital", "2026-04-24", false, "2023-09-06" ], "NCT07279714": [ "COMPLETED", 5, "Sunnybrook Health Sciences Centre", "2026-07-21", false, "2026-01-27" ], "NCT06133634": [ "ACTIVE_NOT_RECRUITING", 70, "University of Colorado, Boulder", "2026-03-31", false, "2023-09-25" ] }, "fisetin_knee_oa_NCT04210986": { "p_values": { "Number of Participants Experiencing One or More Treatment-Emergent Adverse Event": [ ">0.9" ], "Change in Levels of Pro-inflammatory Markers Associated With Senescence": [ "0.9728", "0.9728", "0.0829", "0.9728" ], "Change in Levels of Cartilage Degenerating Markers Associated With OA": [ ">0.99", ">0.99", "0.6594", ">0.99" ], "Change in Physical Function of the Study Knee (6 Min Walk)": [ "0.7480", "0.9572" ], "Change in Physical Function of the Study Knee (Timed-up-and-go Test)": [ ">0.99", ">0.99" ], "Change in Physical Function of the Study Knee (Fast 4-meter Walk)": [ ">0.99", ">0.99" ], "Change in Physical Function of the Study Knee (LEK)": [ "0.130", "0.130" ], "Change in Physical Function of the Study Knee (Stair-Climbing Test)": [ "0.9584", "0.9584" ], "Change in Muscle Strength (Isokinetic Dynamometry)": [ "0.5905", "0.5414" ], "Evaluation of Patient Reported Outcomes (PROs) for Knee Pain": [ ">0.99", ">0.99", ">0.99", ">0.99", ">0.99", ">0.99", ">0.99", ">0.99", ">0.99", ">0.99", ">0.99", ">0.99", ">0.99", ">0.99", ">0.99", ">0.99", ">0.99", ">0.99", ">0.99", ">0.99" ], "Evaluation of Patient Reported Outcomes (PROs) for Knee Function": [ "0.9106", "0.4424", "0.9901" ], "Change in the Quality of Articular Cartilage in the Study Knee With Quantitative Magnetic Resonance Imaging (MRI)": [ ">0.99", ">0.99" ], "Number of Participants Who Convert to Alterative Treatment Within Each Group.": [ "0.474" ] }, "adverse_event_groups": [ [ "Fisetin", 2, 28, 34 ], [ "Placebo", 2, 33, 40 ] ], "lowest_p": 0.0829 }, "note": "Two API v2 searches (query.intr=fisetin; query.intr=dasatinib AND quercetin), merged by NCT ID. Some records test the drugs for cancer, not aging." }, "pubmed": { "dq": { "count": 7, "idlist": [ "40274471", "39823170", "38956196", "37679434", "36857968", "35098970", "30616998" ] }, "fisetin": { "count": 8, "idlist": [ "42218768", "41683255", "36304817", "34809689", "34648968", "33802381", "31434498", "29541713" ] }, "senolytic": { "count": 20, "idlist": [ "42196384", "41619174", "40855191", "40274471", "40261111", "40004995", "39823170", "38956196", "38752873", "38321220", "37679434", "36857968", "36585923", "35914953", "35098970", "34648968", "34181580", "33206062", "33125520", "30616998" ] }, "human_lifespan": { "count": 1, "idlist": [ "35914953" ] }, "queries": { "dq": "(dasatinib[tiab] AND quercetin[tiab]) AND (randomized controlled trial[pt] OR clinical trial[pt])", "fisetin": "fisetin[tiab] AND (randomized controlled trial[pt] OR clinical trial[pt])", "senolytic": "senolytic*[tiab] AND (randomized controlled trial[pt] OR clinical trial[pt])", "human_lifespan": "(senolytic*[tiab] OR dasatinib[tiab] OR fisetin[tiab]) AND (lifespan[tiab] OR life span[tiab] OR longevity[tiab]) AND humans[mh] AND (randomized controlled trial[pt])" } }, "key_trials": [ { "trial": "Lung fibrosis, 2019", "n": 14, "drug": "D+Q", "control": "None", "result": "Walking tests improved", "id": "30616998" }, { "trial": "Kidney disease, 2019", "n": 9, "drug": "D+Q", "control": "None", "result": "Fewer senescent cells", "id": "31542391" }, { "trial": "Lung fibrosis, 2023", "n": 12, "drug": "D+Q", "control": "Placebo", "result": "Feasible; no clear benefit", "id": "36857968" }, { "trial": "Alzheimer's, 2023", "n": 5, "drug": "D+Q", "control": "None", "result": "No change in thinking tests", "id": "37679434" }, { "trial": "Bone, 2024", "n": 60, "drug": "D+Q", "control": "No treatment", "result": "Main goal missed", "id": "38956196" }, { "trial": "Knee arthritis, 2024", "n": 75, "drug": "Fisetin", "control": "Placebo", "result": "No difference vs placebo", "id": "NCT04210986" }, { "trial": "Fatty liver (MASH), 2026", "n": 31, "drug": "D+Q", "control": "Placebo", "result": "Main goal met", "id": "42823536" } ], "key_trials_total_n": 206, "abstract_quotes": { "25754370": { "title": "The Achilles' heel of senescent cells: from transcriptome to senolytic drugs", "journal": "Aging Cell", "year": "2015", "quotes": [ "we describe the rationale for identification and validation of a new class of drugs termed senolytics, which selectively kill senescent cells", "Dasatinib eliminated senescent human fat cell progenitors, while quercetin was more effective against senescent human endothelial cells and mouse BM-MSCs.", "In old mice, cardiac function and carotid vascular reactivity were improved 5 days after a single dose.", "the efficacy of senolytics for alleviating symptoms of frailty and extending healthspan" ] }, "29988130": { "title": "Senolytics improve physical function and increase lifespan in old age", "journal": "Nat Med", "year": "2018", "quotes": [ "intermittent oral administration of senolytics to both senescent cell-transplanted young mice and naturally aged mice alleviated physical dysfunction and increased post-treatment survival by 36% while reducing mortality hazard to 65%", "senolytics can enhance remaining health- and lifespan in old mice" ] }, "30279143": { "title": "Fisetin is a senotherapeutic that extends health and lifespan", "journal": "EBioMedicine", "year": "2018", "quotes": [ "Of the 10 flavonoids tested, fisetin was the most potent senolytic.", "Administration of fisetin to wild-type mice late in life restored tissue homeostasis, reduced age-related pathology, and extended median and maximum lifespan.", "These characteristics suggest the feasibility to translation to human clinical studies." ] }, "35953721": { "title": "Cellular senescence and senolytics: the path to the clinic", "journal": "Nat Med", "year": "2022", "quotes": [ "In preclinical models, interventions targeting those senescent cells that are persistent and cause tissue damage have been shown to delay, prevent or alleviate multiple disorders." ] }, "40437670": { "title": "Intermittent Supplementation With Fisetin Improves Physical Function and Decreases Cellular Senescence in Skeletal Muscle With Aging: A Comparison to Genetic Clearance of Senescent Cells and Synthetic Senolytic Approaches", "journal": "Aging Cell", "year": "2025", "quotes": [ "We found that fisetin mitigated the adverse changes in frailty and grip strength with aging.", "Fisetin had no effects in young mice." ] }, "30616998": { "title": "Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study", "journal": "EBioMedicine", "year": "2019", "quotes": [ "participants with IPF (n = 14)", "The retention rate was 100% with no DQ discontinuation", "One serious adverse event was reported.", "respiratory symptoms (n = 16 total events), skin irritation/bruising (n = 14), and gastrointestinal discomfort (n = 12) being most frequent", "Physical function evaluated as 6-min walk distance, 4-m gait speed, and chair-stands time was significantly and clinically-meaningfully improved (p < .05).", "Pulmonary function, clinical chemistries, frailty index (FI-LAB), and reported health were unchanged.", "warranting evaluation of DQ in larger randomized controlled trials" ] }, "31542391": { "title": "Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney disease", "journal": "EBioMedicine", "year": "2019", "quotes": [ "In an open label Phase 1 pilot study", "D + Q reduced adipose tissue senescent cell burden within 11 days", "Skin epidermal p16INK4A+ and p21CIP1+ cells were reduced, as were circulating SASP factors" ] }, "36857968": { "title": "Senolytics dasatinib and quercetin in idiopathic pulmonary fibrosis: results of a phase I, single-blind, single-center, randomized, placebo-controlled pilot trial on feasibility and tolerability", "journal": "EBioMedicine", "year": "2023", "quotes": [ "Twelve participants with IPF aged >50 years were blinded and randomized at a 1:1 ratio", "While the placebo arm reported fewer overall non-serious AEs (65 vs 22), there were no serious adverse events related to D + Q.", "Sleep disturbances and anxiety were disproportionately represented in the D + Q arm (4/6 vs 0/6).", "these measures do not appear to differ meaningfully between groups", "Intermittently-dosed D + Q in patients with IPF is feasible and generally well-tolerated." ] }, "37679434": { "title": "Senolytic therapy in mild Alzheimer's disease: a phase 1 feasibility trial", "journal": "Nat Med", "year": "2023", "quotes": [ "Five participants (mean age = 76 + 5 years; 40% female) completed the 12-week pilot study.", "D levels were detected in four participants (80%)", "Q was not detected", "The treatment was well-tolerated, with no early discontinuation.", "Secondary cognitive and neuroimaging endpoints did not significantly differ from baseline to post-treatment", "need to be confirmed in fully powered, placebo-controlled studies" ] }, "40274471": { "title": "Evaluation of exploratory fluid biomarkers from a phase 1 senolytic trial in mild Alzheimer's disease", "journal": "Neurotherapeutics", "year": "2025", "quotes": [ "Targeted cytokine and chemokine analyses revealed increases in plasma fractalkine and MMP-7 and CSF IL-6 from baseline to post-treatment.", "Independent validation will be necessary" ] }, "38956196": { "title": "Effects of intermittent senolytic therapy on bone metabolism in postmenopausal women: a phase 2 randomized controlled trial", "journal": "Nat Med", "year": "2024", "quotes": [ "(n = 60 participants)", "did not differ between groups", "(+16%, P = 0.020)", "No serious adverse events were observed.", "intermittent D + Q treatment did not reduce bone resorption in the overall group of postmenopausal women", "increased radius bone mineral density (+2.7%, P = 0.004) at 20 weeks", "the underlying senescent cell burden may dictate the clinical response to senolytics" ] }, "42823536": { "title": "Senolytics dasatinib and quercetin in metabolic dysfunction-associated steatohepatitis: a proof-of-principle randomized, controlled trial", "journal": "Nat Metab", "year": "2026", "quotes": [ "phase-2, double-blind, randomized, placebo-controlled trial", "Thirty-one participants (median age 56 years; 76% male; 58% with type 2 diabetes) were randomized (1:1)", "is achieved in 47% of D + Q-treated participants versus 7% with placebo (P = 0.02)", "MASH resolution occurs more frequently with D + Q than placebo (53% versus 7%; P = 0.02)", "Although adverse events are more frequent in the D + Q group (82% versus 43%), these are all self-limiting.", "this proof-of-principle trial supports the need for future trials of senolytic therapy in fibrotic MASH" ] }, "42834340": { "title": "Therapeutic reversal of cellular senescence: A systematic review of senolytics, senomorphics and anti-ageing therapies in human clinical trials", "journal": "Br J Clin Pharmacol", "year": "2026", "quotes": [ "Six completed clinical studies were included in the evidence synthesis", "evidence remains insufficient to establish clinical efficacy or long-term safety", "Senolytic and senomorphic strategies should therefore be considered investigational rather than established therapies." ] }, "42796982": { "title": "Clinical Translation of Fisetin for Age-Related Diseases: Current Evidence and Future Opportunities", "journal": "Nutrients", "year": "2026", "quotes": [ "we evaluated 34 registered clinical trials", "4 completed trials with available results", "the completed trials indicate that clinical evidence for fisetin remains limited and heterogeneous", "others found no clear or significant clinical benefit" ] }, "42218768": { "title": "12‑weeks fisetin supplementation and interval resistance with aerobic training: changes in Maresin‑1 and inflammatory markers in men with obesity: a randomized controlled trial", "journal": "J Int Soc Sports Nutr", "year": "2026", "quotes": [ "44 obese adult males", "fisetin's anti‑inflammatory properties" ] } }, "conflict_statements": { "29988130": "Patents on senolytic drugs (PCT/US2016/041646) are held by Mayo Clinic.", "31542391": "Patents on senolytic drugs are held by Mayo Clinic.", "36857968": "TT and JK have a financial interest related to this research including patents and pending patents on senolytic drugs, and their uses are held by Mayo Clinic.", "37679434": "J.L.K. and T.T. have a patent for Killing Senescent Cells and Treating Senescence-Associated Conditions Using an SRC Inhibitor and a Flavonoid with royalties paid to Mayo Clinic by Unity Biotechnologies", "38956196": "N.K.L., T.T. and J.L.K. have a financial interest related to this research, including patents and pending patents covering senolytic drugs and their uses that are held by Mayo Clinic.", "42823536": "T.T. and J.L.K. have a financial interest related to this research, including patents and pending patents covering senolytic drugs and their uses held by Mayo Clinic.", "40437670": "The authors declare no conflicts of interest.", "42796982": "The authors declare no conflicts of interest.", "42218768": "No potential conflict of interest was reported by the author(s)." }, "analysis": { "note": "Jabbit analysis. Senolytics are drugs meant to clear senescent ('zombie') cells. The best-known are dasatinib plus quercetin (D+Q) and fisetin. In mice, D+Q increased post-treatment survival in old animals and fisetin extended median and maximum lifespan. No human trial has measured lifespan. Human trials are small (5 to 75 people): early open-label pilots reported better walking tests and fewer senescent cells; a 60-woman bone trial missed its main goal; a 75-person fisetin knee-arthritis trial posted no difference from placebo; an Oct 2026 phase 2 trial in 31 people with fibrotic MASH met its main goal on liver biopsies, with more side effects on D+Q. Dasatinib is a prescription leukemia drug with serious label warnings; quercetin and fisetin are sold as supplements, which FDA does not approve before sale. Patents on senolytic drugs are held by Mayo Clinic, and several trial authors disclose financial interests." } }